Vantage Consulting Group Inc
- SEC CIK
- 0001843547
- Latest filing
- Feb 11, 2026
RPRX holding history
Royalty Pharma plc in every 13F filed by Vantage Consulting Group Inc, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
RPRX overviewAll 13F holders of RPRXFull Q4 2025 holdings
- Shares (Q4 2023)
- 0
- Sold out in Q4 2023
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 11
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q4 2023 | 0 | $0 | 0.0% | −57,500−100.0% | Sold out | Holders |
| Q3 2023 | 57,500 | $1.56M | 1.0% | −593,190−91.2% | Reduced | Holders |
| Q2 2023 | 650,690 | $20.0M | 11.5% | −371,504−36.3% | Reduced | Holders |
| Q1 2023 | 1,022,194 | $36.8M | 20.9% | 00.0% | Unchanged | Holders |
| Q4 2022 | 1,022,194 | $35.5M | 20.9% | 00.0% | Unchanged | Holders |
| Q3 2022 | 1,022,194 | $41.1M | 24.0% | −29,701−2.8% | Reduced | Holders |
| Q2 2022 | 1,051,895 | $44.2M | 24.8% | −1,675,959−61.4% | Reduced | Holders |
| Q1 2022 | 2,727,854 | $106.3M | 41.5% | −1,873,298−40.7% | Reduced | Holders |
| Q4 2021 | 4,601,152 | $183.4M | 49.3% | −3,261,390−41.5% | Reduced | Holders |
| Q3 2021 | 7,862,542 | $284.2M | 60.8% | −1,439,903−15.5% | Reduced | Holders |
| Q2 2021 | 9,302,445 | $381.3M | 66.3% | +596,894+6.9% | Added | Holders |
| Q1 2021 | 8,705,551 | $379.7M | 76.2% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.